

pDUO2-mCD14/TLR2

A plasmid coexpressing the murine CD14 and TLR2 genes

Catalog code: pduo2-mcd14tlr2

<https://www.invivogen.com/pduo-cd14-tlr2>

For research use only

Version 19I23-MM

PRODUCT INFORMATION

Contents

- 20 µg of pDUO2-mCD14/TLR2 provided as lyophilized DNA
- 1 ml of Hygromycin B Gold at 100 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Hygromycin B Gold at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

Toll-Like receptors (TLRs) play a critical role in early innate immunity to invading pathogens by sensing microorganisms. These evolutionary conserved receptors, homologues of the Drosophila Toll gene, recognize highly conserved structural motifs only expressed by microbial pathogens, called pathogen-associated microbial patterns (PAMPs). PAMPs include various bacterial cell wall components such as lipopolysaccharides (LPS), peptidoglycans and lipopeptides, as well as flagellin, bacterial DNA and viral double-stranded RNA. Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK. This signaling cascade leads to the activation of the transcription factor NF-κB which induces the secretion of pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response.

To date, ten toll-like receptors have been reported in humans (TLR1 to TLR10) and only nine in mice (TLR1 to TLR9). In many instances, TLRs require the presence of a co-receptor to initiate the signaling cascade. One example is TLR4 which interacts with MD2 and CD14 to induce NF-κB in response to LPS stimulation.

pDUO2 is an expression vector designed to co-express two TLRs or TLR-related genes known to interact with each other. The genes cloned into pDUO2 comprise the coding sequence (without introns) from the ATG to the Stop codon.

PLASMID FEATURES

- **Murine CD14 (1098 bp)/Murine TLR2 (2352 bp)**
TLR2 is involved in the recognition of multiple products of Gram-positive bacteria, mycobacteria and yeast. The first studies reported that TLR2 mediated LPS response but TLR2 has since been shown to confer responsiveness to the lipopeptides present in LPS preparations. However, it seems that some types of LPS can activate TLR2¹. TLR2 is known to heterodimerize with other TLRs, a property believed to extend the range of PAMPs that TLR2 can recognize. TLR2 cooperates with TLR6 in the response to peptidoglycan² and diacylated mycoplasmal lipopeptide, and associates with TLR1 to recognize triacylated lipopeptides. Furthermore, pathogen recognition by TLR2 is strongly enhanced by CD14.
- **hFerH and hFerL composite promoters:** Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein³. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.
- **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids⁴.
- **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancers⁵.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*⁶
- **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression⁷.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Hph (hygromycin resistance gene):** confers resistance to Hygromycin B both in *E. coli* and mammalian cells. In bacteria, *hph* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *hph* is transcribed from the human FerH composite promoter as a polycistronic mRNA and translated via the FMDV IRES
- **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Hygromycin B usage:

This antibiotic can be used for *E. coli* at 50-100 µg/ml in liquid or solid media and at 50-500 µg/ml to select Hygromycin-resistant mammalian cells.

References

1. Netea MG, et al. 2002. Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? *Trends Immunol*, 23(3):135-9.
2. Ozinsky A, et al. (2000). The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. *PNAS* 97(25):13766-71.
3. Eisenstein RS, and Munro HN. 1990. Translational regulation of ferritin synthesis by iron. *Enzyme* 44(1-4):42-58.
4. Dean DA, et al. 1999. Sequence requirements for plasmid nuclear import. *Exp. Cell. Res.* 253:713-22.
5. Boshart M, et al. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 141(2):521-30.
6. Carswell S., and Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
7. Ramesh N, et al. 1996. High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. *Nucleic Acids Res.* 24(14):2697-700.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



BspHI (3196)

3101 CATTTCCTTGTCTTGCCTCGGCTGCAAGAGCTCTATATTCCAGAAATAAGCTGAAAACACTCCAGATGCTTCGTTGCCCTGTGTTGCTGGCAT
471►er PheSer LeuPheLeuProArgLeuGl nGl uLeuTyr I I eSer ArgAsnLysLeuLysThr LeuProAspAl aSer LeuPheProVal LeuLeuVal Me
3201 GAAAATCAGAGAGAATGCAGTAAGTACTTTCTCAAAGACCAACTTGGTCTTTCCAAACTGGAGACTCTGGAAGCAGGCACAACCACTTGGTCTG
504►tLysI I eArgGl uAsnAl aVal Ser Thr PheSer LysAspGl nLeuGl ySer PheProLysLeuGl uThr LeuGl uAl aGl yAspAsnHi sPheVal Cys
3301 TCCTGCGAACCTCTATCCTTACTATGGAGACGCCAGCTGGCTCAAATCTGGTACTGGCCAGACAGCTACCTGTGACTCTCCGCCTCGCCTGC
538►Ser CysGl uLeuLeuSer PheThr MetGl uThr ProAl aLeuAl aGl nI I eLeuVal AspTrpProAspSer TyrLeuCysAspSer ProProArgLeuH
3401 ACGGCCACAGGCTCAGGATGCCGGCCCTCCGCTTGAAATGTCACCCAGGCTGACTGGTCTGAGTCTGCTGCCCCCTCTCTGTTGATCTGCT
571►sGl yHi sArgLeuGl nAspAl aArgProSer Val LeuGl sGl nAl aAl aLeuVal Ser Gl yVal CysCysAl aLeuLeuLeuI I eLeuLe
3501 CGTAGGTGCCCTGCCCACATTCACGGAGCTGGTACCTGAGAATGATGGGGCTGGCCATGGCCAAGAGGAAGCCCAAGAAAGCTCCCTGCAGG
604►uVal Gl yAl aLeuCysHi sHi sPheHi sGl yLeuTrpTyrLeuArgMet MetTrpAl aTrpLeuGl nAl aLysArgLysProLysAl aProCysArg
3601 GACGTTGCTATGATGCCCTTGGTCTCACGTGAGCAGGATCCCATTGGTGGAGAACCTATGGTCCAGCAGCTGGAGAACTCTGACCCGCCCTTA
638►AspVal CysTyrAspAl aPheVal Ser TyrSer Gl uGl nAspSer Hi sTrpVal Gl uAsnLeuMet Val Gl nGl nLeuGl uAsnSerAspProProPhel
3701 AGCTGTCTCCACAAGCGGGACTCGTCCGGCAAATGGTCAATTGACAACATCATGATTCCATCGAAAAGGCCACAAAAGCTGTGCTGCTTC
671►ysLeuCysLeuHi sLysArgAspPheVal ProGl yLysTrpI I eLeAspAsnI I eLeAspSer I I eGl uLysSer Hi sLysThr Val PheVal LeuSe
3801 TGAGAACCTCGTACGGAGCGAGTGGTCAAGTACGAACCTGGACTTCCACTCAGGCTCTTGACGAGAACACGACGCCATCCTGTTGCTG
704►r Gl uAsnPheVal ArgSer Gl uTrpCysLysTyrGl uLeuAspPheSer Hi sPheArgLeuPheAspGl uAsnAsnAspAl aAl aI I eLeuVal LeuLeu

FspI (3943)

3901 GAGCCATTGAGAGGAAAGCATTCCCAGCGCTCTGCAAACAGATAATGAACACCAAGACCTACCTGGAGTGGCCCTGGATGAAGGCCAGC
738►Gl uProl I eGl uArgLysAl aI I eProGl nArgPheCysLysLeuArgLysI I eMetAsnThr LysThr TyrLeuGl uTrpProLeuAspGl uGl yGl nG
AvrII (4039) NheI (4064)
4001 AGGAAGTGTGTTGGTAAATCTGAGAACTGCAATAAGCTCTGGTCTCCACCCAGTTCTGAGCTAGCTGGCAGACATGATAAGATACTTGTAGAG
771►I nGl uVal PheTrpVal AsnLeuArgThr Al aI I eLysSer ***
4101 TTTGGACAAACCACAACAGTAACTGAGAAAAATGCTTATTGAAATTGATGCTATTGCTTTATTGTAACCATTAAAGCTGCAATAAAC

HpaI (4202)

4201 AAGTTAACAAACAATTGCATTCTATTTATGTTCAGGTTAGGGGAGGTGTTGGAGGTTAAAGCAAGTAAACCTTACAAATGTGGTATGGA

PacI (4304)

4301 AATGTTAACAAACTAGCCATGACCAAAATCCCTAACGTGAGTTTCTGTTCACTGAGCGTCAGACCCGTAGAAAAGATCAAAGGATCTTGTGAGATC
4401 CTTTTTCTGCGCTAATCTGCTGCTGCAAACAAAAACCCGCTACAGCGGGTTGTTGCCGATCAAGAGCTACCAACTCTTTTCCGAA
4501 GGTAACGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTCTAGTGTAGCCGTAGTTAGGCCACACTTCAAGAACTCTGTAGCACCGCCTACATAC
4601 CTCGCTCTGCTAACCTGTTACAGTGGCTGCTCCAGTGGCATAAGTCGTCTTACCGGGTTGGACTCAAGACGATAGTACCGATAAGGCGCAGC

ApalI (4722)

4701 GGTCGGGCTGAACGGGGGTTCTGTCACACAGCCAGCTGGAGCGAACGACCTACACCGAACTGAGATACTACAGCGTGAGCTATGAGAAAGGCCAC
4801 GCTTCCGAAGGGAGAAAGCGGACAGGTATCGGTAAAGCGGAGGGTGGAACAGGAGAGCGCACAGGGAGCTCCAGGGGAAACGCCCTGGTATCTT
4901 TATAGTCCTGCGGTTGCCACCTCTGACTTGAGCGTCGATTTGTGATGCTCGTCAAGGGGGCGGAGCCTATGAAAAACGCCAGCACGCGCC

PacI (5044)

5001 TTTTACGGTTCTGGCTTTGCTGGCTTGTACATGTTCTAACCTGCAAGGGCTGAAATAACCTCTGAAAGAGGAACCTGGTAGGTAC
5101 TTCTGAGGCTGAAAGAACAGCTGTGGAATGTGTGTCAGTTAGGGTGGAAAGTCCCAGGCTCCAGCAGGAGAATGCAAAGCATGCAATCTCA
5201 ATTAGTCAGAACACAGGTGTTGAAAGTCCCAGGCTCCCAGCAGGAGAATGCAAAGCATGCAATCTCAATTAGTCAGCAACCATACTCCACTAGT

BssHII (5309)

NotI (5326)

SandI (5355)

5301 TCCGCCAGAGCGCGAGGGCTCCAGCGGCCCTCCCCACAGCAGGGCGGGCTCCGCACCGGAAGGAGCGGGCTGGGGCGGGCGC
5401 TGATGGCCGGGGCGGCCTGACGCCAGCGCTATAAGAGACCAAGCGACCCGAGGGCCAGACGTTCTGCGCAAGCTTGCCTGAGCAGCAG
5501 GTGAGGGCGGGTGTGCTTCCGGGGCCGGAGCTGGAGGTCTGCTCCAGCGGGCCGGGCCCCGCTGTCGTCGGGGATTAGCTGCGAGCATC
5601 CCGCTTCAGTTGCGGGCGGGAGGCAGAGTGCAGGGCTAGCGCAACCCGTAGCGCTCGCTCGTGTCCGTTGAGGCTAGCGTGGTGTCC
5701 CGCCGCCGCCGTGCTACTCCGGCCGACTCTGGCTTTTTTTGTTGCTGCCCTGCTGCCCTGATTGCCGTTAGCAATAGGGCTAAC
5801 AAGGGAGGGTGCAGGGCTGCTGCCCGAGCCCGAGAGGTATGGTTGGGGAGGAATGGAGGGACAGGAGTGGCGCTGGGGCCCGCCCTCGGA
5901 GCACATGTCCGACGCCACCTGGATGGGCGAGGCCTGGGTTTCCGAAGCAACCAGGCTGGGTTAGCGTGGCGAGGCCATGTGGCCCCAGCACCCG

SmaI (6098)

6001 GCACGATCTGGCTTGGCGGCCCGTGCCTCCCTAACATAGGGTGAGGCCATCCCGTCCGCACAGTGCCTGCGTGGAAAGATGGCCGCTCC
6101 CGGGCCCTGTTGCAAGGAGCTAAATGGAGGACGCCGGAGCCCGGGTGGAGCGGGCGGGTAGTCACCCACACAAAGGAAGAGGGCTGGCCCTCACCG
6201 GCTGCTCTCTGTGACCCCGTGGCTATCGCCGCAATAGTCACCTCGGCTTTGAGCACGGTAGTCGCGGGGGGGAGGGATGTAATGGCGT
6301 TGGAGTTGTTCACATTGGTGGTGAGACTAGTCAGGCCAGCCTGGCGCTGGAGTCATTGGAATTGCTCCCTGAGTTGAGCAGCAGCTAAT

6401 TCTCGGGCTTCTAGCGTTCAAAGGTATCTTAAACCCCTTTAGGTGTTGTAAAACCACCGCTAATTCAAAGCAATCATGGAGCGTGTGCTTGGC
 ApaLI (6518) 
 6501 TTGTTGCTGTTGCTTCTGGCAGCGCTCTCCGCCACCAGAGCCCTGCGAGCTAGACGAGGAAGTTGTTCTGCAACTTCAGATCCAGACGGAG
 7► LeuLeuLeuLeuLeuLeuValHi sAl aSer ProAl aProProGl uProCysGl uLeuAspGl uGl uSer CysSer CysAsnPheSerAspProLysProA
 NotI (6654) XmnI (6668)
 6601 ATTGGTCCAGCGCTTCATTGTTGGGGCGGCAGATGGAATTGTACGGCGCCGCGCAGCTGGAAACCTCTAAAGCGTGTGGACACGGAAAGC
 40► spTrpSer Ser Al aPheAsnCysLeuGl yAl aAl aAspVal Gl uLeuTyrGl yGl yGl yArgSer LeuGl uTyrLeuLeuLysArgValAspThrGl uAl
 BglII (6700)
 6701 AGATCTGGGCAGTTCACTGATATTCAAGTCTCTGCTTAAAGCGGCTTACGGTGGCCGCGGATTCTAGTCGGATTCTATTGGAGCCCTG
 73► aAspLeuGl yGl nPheThrAspI I eLysSer LeuSer LeuLysArgLeuThr ValArgAl aAl aArgI I eProSer ArgI I eLeuPheGl yAl aLeu
 XbaI (6845)
 6801 CGTGTGCTCGGGATTCCGGCCTCCAGGAACCTGACTCTGAAAATCTCGAGGTACCGGCACCGCGCCACCGCTTCTGGAAGCCACCGACCCGATC
 107► ArgVal LeuGl yI I eSer Gl yLeuGl nGl uLeuThr LeuGl uAsnLeuGl uVal Thr Gl yThr Al aProProProLeuLeuGl uAl aThr Gl yProAspL
 6901 TCAACATCTTGAAACCTCCGCAACGTGTCGTGGCAACAAGGGATGCCAGAACCTGAGCAGTGGCTAAAGCCTGGACTCAAGGTACTGAGTAT
 140► euAsnI I eLeuAsnLeuArgAsnVal Ser TrpAl aThr ArgAspAl aTrpLeuAl aGl uLeuGl nGl nTrpLeuLysProGl yLeuLysVal LeuSer I I
 7001 TGCCAAGCACACTCACTCAACTTTCTGCACAGGGTCCGCTTCCCTCCACCTTAGACCTGTCGACAATCTGAATTGGCAGAGA
 173► eAl aGl nAl aHi sSer LeuAsnPheSer CysGl uGl nVal ArgVal PheProAl aLeuSer Thr LeuAspLeuSerAspAsnProGl uLeuGl yGl uArg
 7101 GGACTGATCTCAGCCCTGTCCCCCAAGTCCCACCTCAAGTTAGCCTGCGTAACGGGGATGGAGACGCCAGCGCGTGTGCTCGC
 207► Gl yLeu I I eSer Al aLeuCysProLeuLysPheProThr LeuGl nVal LeuAl aLeuArgAsnAl aGl yMetGl uThr ProSer Gl yVal CysSer Al aL
 PshAI (7232)
 7201 TGGCCGAGCAAGGGTACAGCTGCAAGGACTAGACCTTACTGCGGGATGCTGCAGGCCTCCAGTTGACTGGCCAGTCAGCTAA
 240► euAl aAl aAl aArgVal Gl nLeuGl nGl yLeuAspLeuSer Hi sAsnSer LeuArgAspAl aAl aGl yAl aProSer CysAspTrpProSer Gl nLeuAs
 7301 CTCGCTCAATCTGCTTTCACTGGCTGAAGCAGGTACCTAAAGGGCTGCCAGCAAGCTCAGCTGCTGGATCTCAGTTACAACAGGCTGGATAGGAAC
 273► nSer LeuAsnLeuSer PheThr Gl yLeuLysGl nVal ProLysGl yLeuProAl aLysLeuSer Val LeuAspLeuSer TyrAsnArgLeuAspArgAsn
 7401 CCTAGCCCAGATGAGCTGCCAACGTTGGACTCTAAAGGAATCCCTTTGACTCTGAATCCACTCGGAGAAGTTAACTCTGGCTAG
 307► ProSer ProAspGl uLeuProGl nVal Gl yAsnLeuSer LeuLysGl yAsnProPheLeuAspSer Gl uSer Hi sSer Gl uLysPheAsnSer Gl yVal V
 AvrII (7558)
 7501 TCACCGCCGGAGCTCCATCATCCAAGCAGTGGCTTGTCAAGGAACCTGGCTTGTCTTAGGAGATGCCCTTTGTTAAGGAACATTGCATCCTC
 340► al Thr Al aGl yAl aProSer Ser Gl nAl aVal Al aLeuSer Gl yThr LeuAl aLeuLeuLeuGl yAspArgLeuPheVal •••
 XbaI (7667)
 7601 CTGCTAGGAGCAGGTTCCCAATGACACAAACGTGCAACTGAAACTCCGCTGGCTTTCCAGGTAGAGGGTAACACTTGTACTGCGTTGGC
 7701 TCCACGCTGATCCACTGGCAGTGTAGTAACAGCACTGTTGCTAGCGAGCATGACGGCGTGGAACTCCTCTGGTAACAAGGACCCACGG
 7801 GGCCAAAAGCCACGCCACACGGGCCGTATGTGCAACCCCAGCACGGGACTTTACTGCGAAACCCACTTAAAGTGACATTGAAACTGGTACCCA
 7901 CACACTGGTACAGGCTAAGGATGCCCTCAGGTACCCCGAGGTACACCGCACACTCGGGATCTGAGAAGGGACTGGGCTCTATAAAAGCGCTGG
 8001 TTTAAAAAGCTTCTATGCCGAATAGGTGACCGGAGGTGGCACCTTCTTGCAATTACTGACCCATGAATACAACCTGACTGTTGACAATTAAATCA
 AseI (8092) 
 8101 TCGGCATAGTATATCGGCATAGTATAATACGACTCACTATAGGAGGCCACCATGAAGAACCTGAACGTGACAGCAACTCTGTTGAGAAGTTCTCATT
 1► MetLysLysProGl uLeuThr Al aThr Ser Val Gl uLysPheLeuI I e
 8201 GAAAAATTGATTCTGTTCTGATCTCATGCAGCTGCTGAAGGTGAAGAACAGCAGAGCCTTTCTTGATGTTGGAGGAAGAGGTTATGTTCTGAGGG
 17► Gl uLysPheAspSer Val Ser AspLeuMetGl nLeuSer Gl uGl yGl uGl uSer ArgAl aPheSer PheAspVal Gl yGl yArgGl yTyrVal LeuArgV
 8301 TCAATTCTGTGCTGATGTTTACAAGACAGATATGTTACAGACACTTGCCTCTGCTCTGCCAACCTCAGAAGTTCTGGACATTGGAGAAATT
 50► al AsnSer CysAl aAspGl yPheTyrLysAspArgTyrVal TyrArgHi sPheAl aSer Al aAl aLeuProI I eProGl uVal LeuAspI I eGl yGl uPh
 8401 TTCTGAATCTCACCTACTGCTACAGCAGAAGGACAAAGGAGTCACTCTCAGGATCTCCAGGATCTGGCTGAAACTGAGCTGCCAGCTGTTCTGCAACCTGTTGCT
 83► eSer Gl uSer LeuThr TyrCysI I eSer ArgArgAl aGl yVal Thr LeuGl nAspLeuProGl uThr Gl uLeuProAl aVal LeuGl nProVal Al a
 8501 GAAGCAATTGGATGCCATTGCGAGCTGATCTGAGCCAAACCTGGATTGTCCTTGGTCCCCAAGGCTTGGTCAAGGAGTACACCAACTGGAGGGAT
 117► Gl uAl aMetAspAl aI I eAl aAl aAspLeuSer Gl nThr Ser Gl yPheGl yProPheGl yProGl nGl yI I eGl yGl nTyrThr Thr TrpArgAspP
 8601 TCATTGTCGCAATTGCTGATCTCATGTCATCACTGGCAGACTGTGATGGATGACACAGTTCTGTTCTGCTCAGGCACTGGATGAACCTCATGCT
 150► hel I eCysAl aI I eAl aAspProHi sVal TyrHi sTrpGl nThr Val I MetAspAspThr Val Ser Al aSer Val Al aGl nAl aLeuAspGl uLeuMetLe
 8701 GTGGCAGAAGATTGTCCTGAAGTCAGACACCTGGCCATGCTGATTTGGAGCAACATTTGTTGAGAAGCAACATGTTCTGACAGACAATGGCAGAATCACTGCACTGATTGAC
 183► uTrpAl aGl uAspCysProGl uVal ArgHi sLeuVal Hi sAl aAspPheGl ySerAsnAsnVal LeuThrAspAsnGl yArgI I eThr Al aVal I I eAsp
 8801 TGGTCTGAAGCCATGTTGGAGATTCTCAATATGAGGTTGCCAACATTGTTGGAGACCTGGCTGGCTTGGCATGGAACAAACAAGATATTG
 217► TrpSer Gl uAl aMetPheGl yAspSer Gl nTyrGl uVal Al aAsnI I ePhePheTrpArgProTrpLeuAl aCysMetGl uGl nGl nThr ArgTyrPheG
 8901 AAAGAAGACACCCAGAACACTGGCTGGTCCCCCAGACTGAGAGCCTACATGCTCAGAATTGGCTGGACCAACTGTATCAATCTGGTTGATGGAAACCT
 250► LuArgArgHi sProGl uLeuAl aGl ySer ProArgLeuArgAl aTyrMetLeuArgI I eGl yLeuAspGl nLeuTyrGl nSer LeuValAspGl yAsnPh
 9001 TGATGATGCTGCTGGCACAAGGAAGATGTGATGCCATTGAGGTCTGGTGGACTGTTGAGAAGAACTCAAATTGCAAGAAGGTCTGCTGTT
 283► eAspAspAl aAl aTrpAl aGl nGl yArgCysAspAl aI I eVal ArgSer Gl yAl aGl yThr Val Gl yArgThr Gl nI I eAl aArgArgSer Al aAl aVal

SspI (9177)

9101 TGGACTGATGGATGTGTTGAAGTTCTGGCTGACTCTGGAAACAGGGAGACCCCTCCACAAGACCCAGAGCCAAGGAATGAATTTAGCTAGATTATCCCTAA
317 Trp Thr Asp Glu Cys Val Glu Val Leu Al aAsp Ser Glu Asn Arg Arg Pro Ser Thr Arg Pro Arg Al aLys Glu ***

9201 TACCTGCCACCCACTCTAACATCAGTGGTGGAAAGAACGGTCTCAGAAGTGGTGTTCATTGGCCATTAGTTAGTAGTAAAGACTGGTTAATGAT

9301 ACAATGCATCGAAAACCTTCAGAAGGAAGGAGAATGTTTGACCACTTGGTTCTTTGCGTGTGGCAGTTTAAGTTATTAGTTTAA

9401 AATCAGTACTTTAATGAAACAAC TGACCAAAATTGTCACAGAATTGAGACCCATTAAAAAGTTAAATGAGAAACCTGTGTCCCTTGGT

HpaI (9579)

9501 CAACACCGAGACATTAGGTGAAAGACATCTAATTCTGGTTTACGAATCTGGAAACTTCTTGAAATGTAATTCTTGAGTTAACACTCTGGGTGGAGA

9601 ATAGGGTTTTCCCCCACATAATTGGAAGGGAGGAATATCATTAAAGCTATGGGAGGGTTGCTTGATTACAACACTGGAGAGAAATGCAGCAT

9701 GTTGCTGATTGCCTGTCACTAACACAGGCCAAAAACTGAGTCCTGGTTGCATAGAAAGCTG

